DBV Technologies
Created in 2002
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,766 16,527Activities
Entity types
Location
107 Av. de la République, 92320 Châtillon, France
Châtillon
France
Employees
Scale: 51-200
Estimated: 178
SIREN
441772522Engaged corporates
5
3 0Added in Motherbase
6 years, 1 month ago
deeptech Value proposition
On a mission to advance epicutaneous immunotherapy using our innovative technology platform, ViaskinTM
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, ViaskinTM, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
Allergy, Food and pediatric allergy, and Specific immunotherapyOriginal language
On a mission to advance epicutaneous immunotherapy using our innovative technology platform, ViaskinTM
DBV Technologies is opening up a decisive new approach to the treatment of food allergy demonstrating a significant level of protection, and is associated with an unprecedented safety profile and level of convenience.
DBV Technologies has developed a unique, proprietary, worldwide-patented technology, the Viaskin® patch. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need.
DBV Technologies collaborates closely in its clinical and preclinical programs with the leaders experts in food allergies around the world to be The Expert in Food Allergy through a new mechanism of action with a proprietary technology.
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 8 Jan 2018 | | |
 Starbucks Food and beverage, Retail | Starbucks Food and beverage, Retail | Other 1 Oct 2019 | | |
 Incyte Pharmaceutical, Pharmaceutical Manufacturing | Incyte Pharmaceutical, Pharmaceutical Manufacturing | Other 7 Feb 2022 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 13 Jun 2017 7 Oct 2022 | | |
 Roland Berger Consulting, Business Consulting and Services | Roland Berger Consulting, Business Consulting and Services | Other 7 Oct 2016 | | |